Dr. Bindra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York Street Smilow Cancer Hospital Yale New Haven
Lower Level
New Haven, CT 06510Phone+1 203-200-2100Fax+1 203-785-4622
Education & Training
Memorial Sloan Kettering Cancer CenterResidency, Radiation Oncology, 2008 - 2012
Yale School of MedicineClass of 2007
Certifications & Licensure
CT State Medical License 2012 - 2025
NJ State Medical License 2014 - 2019
NY State Medical License 2008 - 2012
American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM Start of enrollment: 2014 Aug 01
- BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations Start of enrollment: 2020 Jan 03
Publications & Presentations
PubMed
- Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer ...Michael Cecchini, Mary Jo Pilat, Nataliya Uboha, Nilofer S Azad, May Cho
Cancer. 2025-02-15 - Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.Mary Jane Lim-Fat, Julie Bennett, Quinn Ostrom, Mehdi Touat, Enrico Franceschi
Neuro-Oncology. 2025-01-12 - The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma.Matthew McCord, Thomas Sears, Wenxia Wang, Rahul Chaliparambil, Shejuan An
Neuro-Oncology. 2024-12-10
Journal Articles
- Krebs-Cycle-Deficient Hereditary Cancer Syndromes Are Defined by Defects in Homologous-Recombination DNA RepairBrian Shuch, Ranjit S Bindra, Christopher D Corso, Peter M Glazer, Nature
Abstracts/Posters
- PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH InhibitorsRanjit Bindra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...Ranjit Bindra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
Yale Spinout Modifi Biosciences Acquired by MerckOctober 23rd, 2024- Researchers Create 'Chameleon' Compound That Targets Drug-Resistant Brain CancersJune 3rd, 2024
- Yale Cancer Center Experts to Present New Research at Annual AACR MeetingApril 10th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
